Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Fulgent Genetics (FLGT) stock in plain English

Free brief · no signupStart here
FLGTPublished Nov 18, 2026
Fulgent Genetics Inc
Healthcare · Diagnostics & Research
Sells clinical genomic sequencing, specialized anatomic pathology, and molecular diagnostic tests to medical providers.
Assets:
CLIA-certified laboratoriesCore testing sites operate in California, Texas, and Georgia.
Sequencing test catalogCovers thousands of inherited rare diseases and oncology genes.
Therapeutics pipelineConducts early-stage clinical trials for proprietary nanoencapsulated chemotherapy drugs.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

57
OPS ScoreOperating finances
Latest quote
-1.39%$24.78
$692.33M
n/a (loss)
$329.68M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was FLGT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Fulgent Genetics (FLGT) do?

Fulgent Genetics Inc (FLGT) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells clinical genomic sequencing, specialized anatomic pathology, and molecular diagnostic tests to medical providers. The business runs genetic testing, specialized cancer pathology, and drug development on proprietary software systems. It is worth $692.33M on the market and sold $329.68M over the last year.

Market cap
$692.33M
P/E ratio
None (reported a loss)
Annual sales
$329.68M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 18, 2026

Brands and businesses behind FLGT

  • Inform Diagnostics: Provides anatomic pathology laboratory testing to medical practices, earning revenue from medical billing and patient fees.
  • CSI Laboratories: Offers specialized cancer diagnostic services to hospitals and clinics, earning revenue from laboratory testing fees.
  • Picture Genetics: Sells consumer at-home genetic screening kits online, earning revenue directly from customer purchases.

FLGT’s flags, in plain English

Each flag is a number from Fulgent Genetics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 5.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 36% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -27.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about FLGT

How big is Fulgent Genetics?

Fulgent Genetics’ market cap is $692.33M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $329.68M: what customers paid the company over the last year, before any costs.

What is FLGT’s P/E ratio?

FLGT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with FLGT?

Testing revenue remains exposed to commercial insurers and government payers that reduce or deny coverage for genetic panels. That is one risk on Fulgent Genetics’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Fulgent Genetics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. FLGT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card